Concepedia

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Anna Turkova, Hylke Waalewijn, Man K. Chan, Pauline Bollen, Mutsa Bwakura‐Dangarembizi, Adeodata Kekitiinwa, Mark F. Cotton, Abbas Lugemwa, Ebrahim Variava, Grace Miriam Ahimbisibwe,

The Lancet HIV · 2022 · 23 citations · 12 references

DOIFull text

Open access

References

12

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Jan van Lunzen, Franco Maggiolo, José Ramón Arribas et al. · The Lancet Infectious Diseases · 2011 · 295 citations

, , +7

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

Sherene Min, Louis Sloan, Edwin DeJesus et al. · AIDS · 2011 · 212 citations

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin

Kelly E. Dooley, Patrick Sayre, Julie Borland et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2012 · 191 citations

Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

Stephen Castellino, Lee Moss, David S. Wagner et al. · Antimicrobial Agents and Chemotherapy · 2013 · 136 citations · Full text

, , +12

Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial

Kelly E. Dooley, Richard Kaplan, Noluthando Mwelase et al. · Clinical Infectious Diseases · 2019 · 108 citations · Full text